226 related articles for article (PubMed ID: 33714200)
21. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
[TBL] [Abstract][Full Text] [Related]
22. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.
Chen QF; Li W; Wu PH; Shen LJ; Huang ZL
World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872
[TBL] [Abstract][Full Text] [Related]
23. Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma.
Li H; Liu H; Fu H; Li J; Xu L; Wang G; Wu H
Front Immunol; 2021; 12():648812. PubMed ID: 34122408
[TBL] [Abstract][Full Text] [Related]
24. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
25. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
26. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.
Li Y; He X; Zhang X; Xu Y; Wu Y; Xu X
Life Sci; 2021 Jan; 265():118799. PubMed ID: 33220285
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden.
Tang B; Zhu J; Zhao Z; Lu C; Liu S; Fang S; Zheng L; Zhang N; Chen M; Xu M; Yu R; Ji J
J Adv Res; 2021 Nov; 33():153-165. PubMed ID: 34603786
[TBL] [Abstract][Full Text] [Related]
28. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
[TBL] [Abstract][Full Text] [Related]
29. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
Luo JP; Wang J; Huang JH
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34405225
[TBL] [Abstract][Full Text] [Related]
30. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.
Guo Y; Yang J; Ren K; Tian X; Gao H; Tian X; Zhang X; Kan Q
Front Immunol; 2022; 13():861525. PubMed ID: 35355983
[TBL] [Abstract][Full Text] [Related]
31. Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors.
Wang ZM; Xu QR; Kaul D; Ismail M; Badakhshi H
Thorac Cancer; 2021 Jul; 12(13):1995-2006. PubMed ID: 34033229
[TBL] [Abstract][Full Text] [Related]
32. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
33. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
34. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Value of Tumor Mutation Burden and Immune Cell Infiltration in Thymic Epithelial Tumors.
Du H; Xie S; Guo W; Zhang W; Che J; Zhu L; Hang J
Ann Clin Lab Sci; 2021 Jan; 51(1):44-54. PubMed ID: 33653780
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of CD8
Pu Q; Yu L; Liu X; Yan H; Xie Y; Cai X; Wu Y; Du J; Yang Z
Front Immunol; 2024; 15():1375864. PubMed ID: 38650927
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
Luo Y; Chen Q; Lin J
Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
[TBL] [Abstract][Full Text] [Related]
38. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma.
Chan AW; Zhang Z; Chong CC; Tin EK; Chow C; Wong N
J Pathol; 2019 Oct; 249(2):166-172. PubMed ID: 31168847
[TBL] [Abstract][Full Text] [Related]
39. Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Wang Z; Li N; Qi Z; Zhao J; Huang W
Cancer Cell Int; 2021 Jul; 21(1):342. PubMed ID: 34217320
[TBL] [Abstract][Full Text] [Related]
40. Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis.
Cai Y; Wang X; Wang N; Wu J; Ma L; Xie X; Zhang H; Dang C; Kang H; Zhang S; Zhou Z
Life Sci; 2021 Jul; 277():119505. PubMed ID: 33872662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
